Role of MRI in primary brain tumor evaluation.

The NCCN Clinical Practice Guidelines in Oncology for Central Nervous System Cancers use radiologic presentation in the initial evaluation of patients with primary brain tumors and in the determination of response to therapy. The dominant modality use is MRI because of its superior image resolution, speed of acquisition, and high safety profile for patients. The interpretation of MRI is a critical aspect of patient care and evaluation. This article reviews the predominant aspects of MRI for brain tumors, the standard sequences, the criteria to consider in determining treatment response, and advanced aspects currently available. The proper integration of this essential imaging modality into patient care ensures timely disease evaluation and guides the use of therapeutic tools.

[1]  A. Maudsley,et al.  Association of Metabolite Concentrations and Water Diffusivity in Normal Appearing Brain Tissue with Glioma Grade , 2014, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[2]  Seong Ho Park,et al.  Glioma: Application of Histogram Analysis of Pharmacokinetic Parameters from T1-Weighted Dynamic Contrast-Enhanced MR Imaging to Tumor Grading , 2014, American Journal of Neuroradiology.

[3]  W. Mueller,et al.  Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. , 2014, Neuro-oncology.

[4]  Tae Min Kim,et al.  Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging. , 2013, Radiology.

[5]  Achim Seeger,et al.  Comparison of three different MR perfusion techniques and MR spectroscopy for multiparametric assessment in distinguishing recurrent high-grade gliomas from stable disease. , 2013, Academic radiology.

[6]  M. Gilbert,et al.  Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677. , 2013, Neuro-oncology.

[7]  Max Wintermark,et al.  Perfusion MRI: the five most frequently asked clinical questions. , 2013, AJR. American journal of roentgenology.

[8]  T. Mikkelsen,et al.  Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study , 2012, Journal of Neuro-Oncology.

[9]  Benjamin M Ellingson,et al.  Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma. , 2012, Neuro-oncology.

[10]  Bettina Kulle,et al.  Measurements of diagnostic examination performance using quantitative apparent diffusion coefficient and proton MR spectroscopic imaging in the preoperative evaluation of tumor grade in cerebral gliomas. , 2011, European journal of radiology.

[11]  S. Ng,et al.  Differentiation of Brain Abscesses from Necrotic Glioblastomas and Cystic Metastatic Brain Tumors with Diffusion Tensor Imaging , 2011, American Journal of Neuroradiology.

[12]  Sunita Ghosh,et al.  Changes in serial magnetic resonance spectroscopy predict outcome in high-grade glioma during and after postoperative radiotherapy. , 2011, Anticancer research.

[13]  T. Cloughesy,et al.  Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. , 2011, Neuro-oncology.

[14]  T. Mikkelsen,et al.  Differentiating treatment-induced necrosis from recurrent/progressive brain tumor using nonmodel-based semiquantitative indices derived from dynamic contrast-enhanced T1-weighted MR perfusion. , 2011, Neuro-oncology.

[15]  L Junck,et al.  Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. , 2011, The Lancet. Oncology.

[16]  Timothy D Johnson,et al.  Prospective Analysis of Parametric Response Map–Derived MRI Biomarkers: Identification of Early and Distinct Glioma Response Patterns Not Predicted by Standard Radiographic Assessment , 2011, Clinical Cancer Research.

[17]  M. Julià-Sapé,et al.  Proton MR Spectroscopy Provides Relevant Prognostic Information in High-Grade Astrocytomas , 2010, American Journal of Neuroradiology.

[18]  P. Barker,et al.  Imaging of brain tumors: MR spectroscopy and metabolic imaging. , 2010, Neuroimaging clinics of North America.

[19]  C. Daumas-Duport,et al.  Diffuse low-grade oligodendrogliomas extend beyond MRI-defined abnormalities , 2010, Neurology.

[20]  K. Hoang-Xuan,et al.  Microvascular leakage and contrast enhancement as prognostic factors for recurrence in unfavorable low-grade gliomas , 2010, Journal of Neuro-Oncology.

[21]  M. J. van den Bent,et al.  Pseudoprogression and pseudoresponse in the treatment of gliomas , 2009, Current opinion in neurology.

[22]  Olga Ciccarelli,et al.  Low-grade gliomas: six-month tumor growth predicts patient outcome better than admission tumor volume, relative cerebral blood volume, and apparent diffusion coefficient. , 2009, Radiology.

[23]  Toshinori Hirai,et al.  Grading astrocytic tumors by using apparent diffusion coefficient parameters: superiority of a one- versus two-parameter pilot method. , 2009, Radiology.

[24]  Soonmee Cha,et al.  Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma , 2009, Journal of Neuro-Oncology.

[25]  Susan Chang,et al.  Pseudoprogression and pseudoresponse: Challenges in brain tumor imaging , 2009, Current neurology and neuroscience reports.

[26]  M Kirkpatrick,et al.  Cerebral Blood Volume Measurements by Perfusion-Weighted MR Imaging in Gliomas: Ready for Prime Time in Predicting Short-Term Outcome and Recurrent Disease? , 2009, American Journal of Neuroradiology.

[27]  Luc Taillandier,et al.  Prognostic significance of imaging contrast enhancement for WHO grade II gliomas. , 2009, Neuro-oncology.

[28]  Inas S. Khayal,et al.  Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM , 2009, Journal of Neuro-Oncology.

[29]  S. Ng,et al.  Differentiation Between Classic and Atypical Meningiomas with Use of Diffusion Tensor Imaging , 2008, American Journal of Neuroradiology.

[30]  Dieta Brandsma,et al.  Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide , 2008, Cancer.

[31]  Timothy D Johnson,et al.  Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Dieta Brandsma,et al.  Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. , 2008, The Lancet. Oncology.

[33]  S. Ng,et al.  Primary Cerebral Lymphoma and Glioblastoma Multiforme: Differences in Diffusion Characteristics Evaluated with Diffusion Tensor Imaging , 2008, American Journal of Neuroradiology.

[34]  P. Baraldi,et al.  Multimodal MRI in the characterization of glial neoplasms: the combined role of single-voxel MR spectroscopy, diffusion imaging and echo-planar perfusion imaging , 2007, Neuroradiology.

[35]  Laurent Capelle,et al.  Dynamic history of low‐grade gliomas before and after temozolomide treatment , 2007, Annals of neurology.

[36]  Hong Liu,et al.  Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury , 2007, Journal of Neuro-Oncology.

[37]  V. Levin,et al.  Effect of bevacizumab on radiation necrosis of the brain. , 2007, International journal of radiation oncology, biology, physics.

[38]  Bahattin Hakyemez,et al.  Evaluation of different cerebral mass lesions by perfusion‐weighted MR imaging , 2006, Journal of magnetic resonance imaging : JMRI.

[39]  Christopher Nimsky,et al.  Gliomas: histopathologic evaluation of changes in directionality and magnitude of water diffusion at diffusion-tensor MR imaging. , 2006, Radiology.

[40]  A. W. Simonetti,et al.  Development of a decision support system for diagnosis and grading of brain tumours using in vivo magnetic resonance single voxel spectra , 2006, NMR in biomedicine.

[41]  C. Nimsky,et al.  Implementation of Fiber Tract Navigation , 2006, Neurosurgery.

[42]  Christopher Nimsky,et al.  Implementation of fiber tract navigation. , 2006, Neurosurgery.

[43]  B. Nan,et al.  Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy. , 2005, AJR. American journal of roentgenology.

[44]  I. Ercan,et al.  High-grade and low-grade gliomas: differentiation by using perfusion MR imaging. , 2005, Clinical radiology.

[45]  Michael H Lev,et al.  Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. , 2004, AJNR. American journal of neuroradiology.

[46]  J. Rees.  Advances in magnetic resonance imaging of brain tumours , 2003, Current opinion in neurology.

[47]  A Gregory Sorensen,et al.  The potential of proton magnetic resonance spectroscopy (1H-MRS) in the diagnosis and management of patients with brain tumors , 2002, Current opinion in oncology.

[48]  T. Mikkelsen,et al.  Correlation between Magnetic Resonance Spectroscopy Imaging and Image-guided Biopsies: Semiquantitative and Qualitative Histopathological Analyses of Patients with Untreated Glioma , 2001, Neurosurgery.

[49]  L Verhey,et al.  Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery. , 2001, AJNR. American journal of neuroradiology.

[50]  W P Dillon,et al.  Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. , 2001, AJNR. American journal of neuroradiology.

[51]  J. Britton,et al.  FLAIR imaging in the follow-up of low-grade gliomas: time to dispense with the dual-echo? , 2001, Neuroradiology.

[52]  M. Heesters,et al.  Localized proton spectroscopy of inoperable brain gliomas. Response to radiation therapy , 1993, Journal of Neuro-Oncology.

[53]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  S. Ekholm,et al.  Correlation between progression free survival and dynamic susceptibility contrast MRI perfusion in WHO grade III glioma subtypes , 2013, Journal of Neuro-Oncology.

[55]  M. Essig,et al.  Perfusion MRI: the five most frequently asked technical questions. , 2013, AJR. American journal of roentgenology.

[56]  B. Hakyemez,et al.  Solitary metastases and high-grade gliomas: radiological differentiation by morphometric analysis and perfusion-weighted MRI. , 2010, Clinical radiology.

[57]  J. Uhm.  Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group , 2010 .

[58]  A. Waldman,et al.  Clinical MR Neuroimaging: Magnetic resonance spectroscopy in adult neoplasia , 2009 .

[59]  P. Barker,et al.  Clinical MR Neuroimaging: Physiological and Functional Techniques , 2009 .

[60]  S. R. Shepard,et al.  Improved Delineation of Glioma Margins and Regions of Infiltration with the Use of Diffusion Tensor Imaging: An Image-Guided Biopsy Study , 2008 .

[61]  P. Kelly,et al.  Perfusion Magnetic Resonance Imaging Predicts Patient Outcome as an Adjunct to Histopathology: A Second Reference Standard in the Surgical and Nonsurgical Treatment of Low-grade Gliomas. , 2006, Neurosurgery.